A common treatment for anemia — a deficiency in red blood cells (rbcs) caused by their insufficient production, excessive destruction, or excessive loss — is administration of recombinant erythropoietin (Epo), a hormone that stimulates the production of rbc precursors by the bone marrow.
Unfortunately, many patients with anemia do not respond to treatment with Epo. However, a new study in mice, by Anne Angelillo-Scherrer and her colleagues at the University Hospital Center and University of Lausanne, Switzerland, has indicated that the protein Gas6 might augment or replace Epo in the treatment of patients who are hyporesponsive or resistant to Epo, respectively.
It was shown that following treatment with Epo, mouse rbc precursors released Gas6, which increased cell signaling in response to Epo treatment. In addition, mice deficient in Gas6 had decreased sensitivity to Epo and a reduced ability to recover from anemia. Administration of Gas6, either alone or in combination with Epo, was successful at treating both chronic and acute anemia in mice.
The authors therefore concluded that Gas6 has a role in rbc formation and might have valuable therapeutic potential for the treatment of individuals with anemia who fail to respond to treatment with Epo.
Source: Journal of Clinical Investigation
Related stories:
Researchers find gene linked to severe diabetic eye and kidney diseases
Researchers at the John A. Moran Eye Center at the University of Utah and collaborative institutions have identified a gene called erythropoietin (EPO) that contributes to increased risk of severe diabetic eye and kidney diseases, called retinopathy and nephropathy.
Mice Can Sense Oxygen Through Skin
Biologists at the University of California, San Diego have discovered that the skin of mice can sense low levels of oxygen and regulate the production of erythropoietin, or EPO, the hormone that stimulates our bodies to produce red blood cells and allows us to adapt to high-altitude, low-oxygen environments.
Twin findings raise hopes of improved anemia treatments
A new understanding of how red blood cell production is controlled could lead to improvements in the treatment of the blood disorder anaemia, according to West Australian medical researchers.
Drug for anemic cancer patients raises risk of death
Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy. But a new study by Northwestern University's Feinberg School of Medicine shows these drugs, called erythropoiesis-stimulating agents (ESAs), actually raise patients' risk of death, possibly by stimulating the growth of cancer cells.
New discovery leaves blood-doping athletes scratching their heads
A stunning discovery by German scientists may make blood doping and the treatment of severe anemia as easy as washing your hair. In the October print issue of
The FASEB Journal, researchers show that the estimated 100,000 hair follicles on each person’s head have the potential to become erythropoietin (EPO) factories. EPO, the hormone primarily responsible for the creation of red blood cells, is used illegally to enhance athletic performance and is used legally to treat severe anemia associated with kidney failure and chemotherapy.
Memory enhanced by sports-cheat drug
A drug used to increase blood production in both medical treatments and athletic doping scandals seems also to improve memory in those using it. New research published in the open access journal
BMC Biology shows that the memory enhancing effects of erythropoietin (EPO) are not related to its effects on blood production but due to direct influences on neurons in the brain. The findings may prove useful in the treatment of diseases affecting brain function, such as schizophrenia, multiple sclerosis, and Alzheimer's.
New study examines the validity of epo testing
Recombinant human erythropoietin (rHuEpo) is a genetically engineered hormone sometimes misused by high-performance athletes such as cyclists and marathon runners to boost their endurance. The potential misuse of the drug is detected in urine collected from athletes. Since the test was introduced in 2000, 33 labs around the world have been accredited by the World Anti-Doping Agency (WADA) to administer the procedure.
Anemia drugs under scrutiny
U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.